Toxicology News and Research

Latest Toxicology News and Research

VGX International, Inovio partner to co-develop SynCon vaccines for hepatitis B and C infections

Inovio Pharmaceuticals, Inc., a leader in the development of synthetic vaccines against cancers and infectious diseases, announced today that it has entered into a product development collaboration agreement with its affiliate, VGX International Inc., to co-develop Inovio's SynCon therapeutic vaccines for hepatitis B and C infections.

10 Oct 2011

University of Leicester's public lectures to explore reality of toxic damage

The genetic and biochemical consequences of exposure to toxins and mutagens are the theme of the next in a series of accessible lecture events at the University of Leicester.

7 Oct 2011

Tips on how to prevent unnecessary medication/supplement mishaps

Navigating the supplement and medication maze can get confusing especially when you have multiple prescriptions. It is important to organize yourself with your medications and supplements to prevent unnecessary mishaps.

7 Oct 2011

USDTL releases CordStat EtOH assay screens for newborn alcohol exposure in utero

United States Drug Testing Laboratories (USDTL), a reference laboratory specializing in alcohol and drugs of abuse testing, released a new assay testing umbilical cord for newborn alcohol exposure in utero on Monday, October 3, 2011.

3 Oct 2011

ViroPharma licenses worldwide rights from Intellect Neurosciences to OX1 for treatment of FA

ViroPharma Incorporated today announced the license of worldwide rights from Intellect Neurosciences, Inc. to its clinical stage drug candidate, OX1, being developed for the treatment of Friedreich's Ataxia (FA), a rare, hereditary, progressive neurodegenerative disease.

1 Oct 2011

Circadian subsidiary submits IND application to FDA to initiate VGX-100 study against cancer

Circadian Technologies Limited is extremely proud to announce that its 100% owned subsidiary, Vegenics Pty Ltd, has submitted an investigational new drug application to the U.S. Food and Drug Administration to initiate clinical studies of VGX-100.

1 Oct 2011

Circadian files IND with FDA for VGX-100 for the treatment of cancer patients with solid tumors

Circadian Technologies Limited (ASX: CIR, OTCQX:CKDXY) is extremely proud to announce that its 100% owned subsidiary, Vegenics Pty Ltd, has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate clinical studies of VGX-100. The first trial (Phase I) will involve the treatment of a variety of different cancer types in patients with late stage cancer.

29 Sep 2011

InterMune reports new data from Esbriet clinical trial on IPF

InterMune, Inc. today reported that new data was presented at the European Respiratory Society (ERS) Annual Congress supporting the longer-term safety and tolerability of Esbriet(pirfenidone) in patients with idiopathic pulmonary fibrosis (IPF), a devastating lung disease.

26 Sep 2011

Three Johns Hopkins scientists receive NIH Director's New Innovator Awards

A pioneer in the field of epigenetics who has been spearheading the use of genome-wide technology for epigenetics research, a researcher who has revealed a weakness in the tuberculosis bacterium that makes it more susceptible to antibiotics, and a scientist who seeks to revolutionize new methods for toxicological testing to improve human health and reduce animal testing have received Director's Awards from the National Institutes of Health.

22 Sep 2011

Silence Therapeutics reports revenue of £354,078 for six months ended 30 June 2011

Silence Therapeutics Plc, a leading international RNAi therapeutics company, today provides a corporate update and announces its interim results for the six months ended 30 June 2011.

21 Sep 2011

Combination of lunasin and oxaliplatin prevents colon cancer from metastasis

A University of Illinois study reports a promising new weapon in treating metastatic colon cancer, particularly in patients who have developed resistance to chemotherapy.

20 Sep 2011

Preclinical studies shows EmPAC more effective than Taxol

Cornerstone Pharmaceuticals, Inc. has announced the publication of data from preclinical studies on EmPAC™, its nanoparticle reformulation of paclitaxel, in the August issue of the Journal of Nanoscience and Nanotechnology. The publication highlights data demonstrating improved safety and efficacy of EmPAC™ versus Taxol®, the generic formulation of paclitaxel and one of the most widely prescribed chemotherapies. EmPAC™ is a nanoemulsion formulation of Paclitaxel and is the lead product candidate of Cornerstone’s proprietary Emulsiphan™ cancer selective delivery nanotechnology platform. Taxol®, an injectable formulation of Paclitaxel, is currently used to treat a variety of cancers, including ovarian carcinomas, breast cancer, non-small cell lung cancer, and AIDS-related Kaposi’s sarcoma.

19 Sep 2011

Too many kids poisoned with prescription drugs: Study

Figures show that each year half a million kids age 5 and younger get into household medications and are poisoned. Though parents tend to believe that these tragic accidents will never happen to their kids, Dr. Randall Bond, a leading advocate for better prescription drug safety in the home, believes it can happen to anyone.

19 Sep 2011

Aestus to develop ATx09-002 for treatment of neuropathic pain

Aestus Therapeutics, Inc. and Prosidion Ltd., a wholly owned subsidiary of Astellas Pharma Inc., announced today a license agreement providing Aestus with exclusive, world-wide rights to the Prosidion investigational product PSN-357.

19 Sep 2011

Study shows increase in pediatric medication poisoning

The number of young children admitted to hospitals or seen in emergency departments because they unintentionally took a potentially toxic dose of medication has risen dramatically in recent years, according to a new Cincinnati Children's Hospital Medical Center study.

16 Sep 2011

Hengrui, Shanghai ChemPartner enter strategic development partnership for monoclonal antibodies

ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, and Jiangsu Hengrui Medicine Co., Ltd., a leading Chinese pharmaceutical company, today announced that Shanghai ChemPartner, a wholly owned subsidiary of ShangPharma, and Hengrui have entered into a strategic partnership for the development of novel therapeutic monoclonal antibodies.

15 Sep 2011

Scientists decode new mechanism that regulates cell polarity in epithelial tissues, neurons

In the course of examining the Drosophila tumor suppressor gene (Dlg), scientists at the Helmholtz Zentrum München have succeeded in decoding a new mechanism that regulates cell polarity in epithelial tissues or in neurons in the brain.

14 Sep 2011

Natural S-equol supplement does not increase risk of estrogen-sensitive breast cancer

Consuming the soy germ-based compound Natural S-equol and the supplement SE5-OH containing Natural S-equol did not increase the risk of estrogen-sensitive breast cancer, according to a study in the September issue of the peer-reviewed journal Food and Chemical Toxicology.

14 Sep 2011

FDA announces organizational changes within CDER's Office of Oncology Drug Products

Today, the U.S. Food and Drug Administration announced organizational changes within the office responsible for reviewing all drug and biologic applications for cancer therapies.

13 Sep 2011

InterMune to launch Esbriet for German patients with IPF

InterMune, Inc. today announced that Esbriet will be offered to patients in Germany beginning September 15, 2011. This will mark the first time Esbriet will be commercially available in Europe since it was approved by the European Commission in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF), a devastating and fatal lung disease.

12 Sep 2011

Toxicology News and Research

Latest Toxicology News and Research

VGX International, Inovio partner to co-develop SynCon vaccines for hepatitis B and C infections

University of Leicester's public lectures to explore reality of toxic damage

Tips on how to prevent unnecessary medication/supplement mishaps

USDTL releases CordStat EtOH assay screens for newborn alcohol exposure in utero

ViroPharma licenses worldwide rights from Intellect Neurosciences to OX1 for treatment of FA

Circadian subsidiary submits IND application to FDA to initiate VGX-100 study against cancer

Circadian files IND with FDA for VGX-100 for the treatment of cancer patients with solid tumors

InterMune reports new data from Esbriet clinical trial on IPF

Three Johns Hopkins scientists receive NIH Director's New Innovator Awards

Silence Therapeutics reports revenue of £354,078 for six months ended 30 June 2011

Combination of lunasin and oxaliplatin prevents colon cancer from metastasis

Preclinical studies shows EmPAC more effective than Taxol

Too many kids poisoned with prescription drugs: Study

Aestus to develop ATx09-002 for treatment of neuropathic pain

Study shows increase in pediatric medication poisoning

Hengrui, Shanghai ChemPartner enter strategic development partnership for monoclonal antibodies

Scientists decode new mechanism that regulates cell polarity in epithelial tissues, neurons

Natural S-equol supplement does not increase risk of estrogen-sensitive breast cancer

FDA announces organizational changes within CDER's Office of Oncology Drug Products

InterMune to launch Esbriet for German patients with IPF

Forensics and toxicology - Industry Focus eBook eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Toxicology News and Research

Latest Toxicology News and Research

Forensics and toxicology - Industry Focus eBook eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in